WGS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
GeneDx Holdings Corp (WGS) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's strong revenue growth, positive news catalysts, and attractive valuation as highlighted by analysts outweigh the short-term insider selling and negative net income trends. The stock's potential for long-term appreciation, supported by its competitive moat and growth runway, makes it a compelling investment opportunity.
The MACD is positive and expanding, signaling bullish momentum. However, the RSI is neutral, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5), indicating a mixed trend. The current price is above the pivot level of 91.473, with resistance levels at 99.262 and 104.074, suggesting room for upward movement.
Wells Fargo upgraded the stock to Overweight, citing an attractive valuation and growth runway.
GeneDx's recent FDA Breakthrough Device Designation for its genome testing.
Positive news about the company's leadership and participation in public-private partnerships.
Revenue growth of 51.86% YoY in Q3 2025.
Insider selling has increased significantly by 359.34% over the last month.
Net income and EPS have declined YoY, indicating profitability challenges.
In Q3 2025, revenue increased by 51.86% YoY to $116.74M, and gross margin improved to 72.4%, up 16.36% YoY. However, net income dropped by 8.14% YoY to -$7.64M, and EPS declined by 12.90% YoY to -0.27.
Analysts are bullish on the stock. Wells Fargo upgraded the stock to Overweight with a $155 price target, citing an attractive valuation and growth runway. Canaccord maintains a Buy rating with a $170 price target, highlighting the company's innovative GenomeDx Prenatal test and its entry into a lucrative market.
